A phase 3 randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to eltrombopag in patients with primary immune thrombocytopenia (ITP) who had an insufficient response or relapsed after first line steroid treatment (VAYHIT2)

Authors
Category Primary study
Registry of TrialsOverview of Medical Research in the Netherlands
Year 2022
This article has no abstract
Epistemonikos ID: f75c360f3c5893a5c25a88f36a2df0a7f92b16b0
First added on: Apr 11, 2025